Published By: Syndicate Market Research
Nonalcoholic Steatohepatitis Market - Global
Industry Perspective, Comprehensive Analysis
and Forecast, 2014 – 2020
Joel John
3422 SW 15 Street, Suit #8138,
Deerfield Beach,
Florida 33442, USA
Tel: +1-386-310-3803
Toll Free: 1-855-465-4651
sales@SyndicateMarketResearch.com
http://www.syndicatemarketresearch.com/
Nonalcoholic Steatohepatitis Market
Nonalcoholic steatohepatitis (NASH) is liver inflammation and damage caused by a buildup of fat in the liver. It
is also known as silent liver disease. It is a type of nonalcoholic fatty liver disease (NAFLD), which mainly
affects people with diabetes and obesity. Nonalcoholic Steatohepatitis (NASH) is defined by histological
hallmarks of inflammation, hepatic steatosis, cell death, and fibrosis. A number of drugs used to treat medical
situation have been NASH, such as amiodarone (Corderone, Pacerone), tamoxifen (Nolvadex), perhexiline
maleate (Pexhid) and steroids (eg, prednisone). Medical studies have identified a strong connection of NASH
with certain risk factors such as insulin resistance, oxidative stress and release of toxic inflammatory proteins.
Nonalcoholic steatohepatitis is a gradually becoming common chronic liver disease around the world and is
closely related with diabetes and obesity. Rising incidence of NAFLD cases, changing lifestyle patterns,
increasing rate of obesity and diabetes, and initiatives for research and development are the major driving
factors of this market. However, insufficient information about the pathophysiology of NASH tissue and
ineffective diagnostic technology for NASH is considered to restraint in this market.
Get Full Detail @ http://www.syndicatemarketresearch.com/marketanalysis/nonalcoholic-steatohepatitis-market.html
The report includes detailed competitive landscape of the global nonalcoholic steatohepatitis market and an
analysis of Porter’s five forces model for the nonalcoholic steatohepatitis...